The American Food and Drug Administration (FDA) has just approved a cancer drug which is based on the research efforts of a German scientist. Axel Ullrich, director of the Max-Planck-Institute for Biochemistry in Martinsried, laid the groundwork on which the active substance Sunitinib was based. ThePharmaceutical group Pfizer has now brought the Sunitinib-based product SUTENT® on to the[…]